PulseAugur
EN
LIVE 21:17:16
中文(ZH) 以岭药业：全资子公司他达拉非片获得药品注册证书

Yiling Pharma subsidiary receives drug registration certificate for Tadalafil tablets

By PulseAugur Editorial · [1 sources] ·

Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received a drug registration certificate from China's National Medical Products Administration for its Tadalafil tablets. This approval grants the subsidiary the qualification to sell the drug in the domestic market. The company stated that this development is not expected to have a significant impact on its current operating performance. AI

RANK_REASON This is a product approval for a pharmaceutical subsidiary, not a core AI release or significant industry event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Yiling Pharma subsidiary receives drug registration certificate for Tadalafil tablets

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
This is a product approval for a pharmaceutical subsidiary, not a core AI release or significant industry event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
92 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Yiling Pharmaceutical: Wholly-owned subsidiary Tadalafil Tablets obtain Drug Registration Certificate

    36氪获悉，以岭药业公告，近日，公司全资子公司以岭万洲国际制药有限公司（简称“以岭万洲”）向国家药品监督管理局药品审评中心申报的他达拉非片的上市许可申请，获得国家药品监督管理局的批准，取得药品注册证书。该药品剂型为片剂，规格为20mg，注册分类为化学药品4类。本次他达拉非片获得注册批件，标志着以岭万洲具备了在国内市场销售该产品的资格，不会对公司当期经营业绩产生重大影响。药品的生产销售容易受市场政策环境变化、市场竞争等因素的影响。

RELATED TOPICS